1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...
Another Wall Street Bull Cuts S&P 500 Target. It Misread Trump on Tariffs.
Investors have rapidly been losing faith in the stock market—one of Wall Street’s most prominent bulls just joined their ...
Wall Street's S&P 500 forecast range is widening: Chart of the Week
With stocks struggling out of the gate in 2025, a wide range of Wall Street forecasts, both positive and negative, feel like ...
Wall Street analyst overhauls S&P 500 price target as markets gyrate
Stocks rebounded firmly on Friday, with the S&P 500 recording its strongest gain of the year, but they remain firmly in the ...
1 Wall Street Analyst Thinks Palantir Stock Is Going to $60. Is It a Sell?
Following Palantir Technologies ' ( PLTR 2.53%) recent customer event, Jefferies analyst Brent Hill maintained an ...
Another strategist chops his S&P 500 target — but for a different reason than the Goldman Sachs reduction
Another day, another S&P 500 target cut. The reduction by Ed Yardeni, president and chief investment strategist of Yardeni ...
Why this Wall Street strategist says investors should stick with U.S. stocks despite recession fears
Oppenheimer’s John Stoltzfus, the most bullish strategist on Wall Street with a target for the S&P 500 to hit 7,100 by the ...
24/7 Wall St. on MSN10d
Wall Street Price Prediction: NVIDIA's Share Price Forecast for 2025
Chipmaking giant and Magnificent Seven member Nvidia (NASDAQ:NVDA) is among the top growth stocks investors continue to keep ...
2 Artificial Intelligence (AI) Stocks With 41% or More Upside, According to Wall Street Analysts
The potential for artificial intelligence (AI) to improve the fortunes of leading businesses has been a huge catalyst for the ...
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Here's what investors need to know about this small-cap biotech company. Iovance ...
Tesla is struggling. One Wall Street analyst sees red-state EV buyers coming to the rescue.
"Tesla could actually net meaningful sales gains over time," TD Cowen analysts wrote this week. Sales could ultimately grow ...
Here’s what Wall Street is saying about Micron ahead of earnings
Micron Technology (MU) is scheduled to report results of its fiscal second quarter after the market close on Thursday, March 20, with a ...